Wednesday, June 10, 2026

Intelligence Β· Clinical Development

Pipeline search results

Programs matching β€œomid” across our ClinicalTrials.gov index β€” phase, modality, sponsor, and trial IDs.

Matching programs 143
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 143 pipeline programs matching "omid" from NovaPharmaNews Clinical Development Intelligence β€” phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

143 results for β€œomid” Back to intelligence hub

Search results

Page 4 of 6
  1. Leflunomide 20 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial
  2. Lenalidomide (CC-5013)

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial
  3. Lenalidomide or Pomalidomide

    ONCOLYTICS BIOTECH INC

    Multiple Myeloma

    phase 1 small molecule active

    1 trial
  4. Sublingual film containing BXCL501 (Dexmedetomidine)

    BioXcel Therapeutics

    Agitation

    phase 1 small molecule completed

    1 trial
  5. Tebipenem Pivoxil Hydrobromide

    Spero Therapeutics

    Diabetes

    phase 1 small molecule completed

    1 trial
  6. Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo

    Spero Therapeutics

    TQT Study

    phase 1 small molecule completed

    1 trial
  7. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  8. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  9. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  10. pomalidomide

    Celgene Europe Limited

    Multiple Myeloma in Relapse

    phase 1 small molecule completed

    1 trial
  11. 0.3% ropivacaine and 50 ΞΌg dexmedetomidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Free Flap Reconstruction

    approved small molecule active

    1 trial
  12. Camrelizumab + chemotherapy+Thalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    approved small molecule active

    1 trial
  13. Dexmedetomidine

    The University of Hong Kong

    Anxiety, Separation

    approved small molecule active

    1 trial
  14. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial
  15. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Overall Survival

    approved small molecule completed

    1 trial
  16. Dexmedetomidine

    Hospital Authority, Hong Kong

    Thyroid Diseases

    approved small molecule active

    1 trial
  17. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Postoperative Delirium After Living Donor Renal Transplantation

    approved small molecule active

    1 trial
  18. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Renal Function

    approved small molecule active

    1 trial
  19. Dexmedetomidine

    Peking University Third Hospital

    Aged

    approved small molecule completed

    1 trial
  20. Dexmedetomidine

    Peking University Third Hospital

    Breast Cancer

    approved small molecule completed

    1 trial
  21. Dexmedetomidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lower Limb Fracture

    approved small molecule completed

    1 trial
  22. Dexmedetomidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Post-Surgical Pain

    approved small molecule active

    1 trial
  23. Dexmedetomidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thoracic Paravertebral Blocks

    approved small molecule terminated

    1 trial
  24. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Elderly

    approved small molecule completed

    3 trials

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs β€” not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars β€” improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes β€” use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.